Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (December 2019)
25 slides from Adherium's investor presentation, Dec 19, 2019
Slide 1: Adherium December 2019 Update Presentation
Adherium Limited Collins Square, Tower 4 Level 18, 727 Collins Street Melbourne VIC 3000 Australia Level 11, 16 Kingston Street Auckland 1010 New Zealand 19 December 2019 Companies Announcements Office ASX Limited Dear Sir/Madam Adherium December 2019 Update Presentation Adherium Limited ACN 605 352
Slide 2: Introductory Summary
INTRODUCTORY SUMMARY A Digital Health Company focused on Medication Adherence, with the market leading Respiratory Solution December 2019
Slide 3: Disclaimer and Forward Looking Statement
Disclaimer and Forward Looking Statement The following material is of a general nature and has only been prepared These risks and uncertainties include, but are not limited to: (i) the as a presentation aid. This presentation does NOT contain all of the possible delays in and the outcome of product
Slide 4: Adherium Overview
adherium Overview • Digital health company, founded in patients, providers and payers 2001 and listed on ASX in 2015 • Hailie® technology has been shown • A leader in providing connected to improve adherence and reduce health solutions with a primary focus the frequency of negative outcomes on enhan
Slide 5: Executive Summary
Executive Summary MARKET INFLECTION 18 MONTH SHAREHOLDER NEW LEADERSHIP POINTS COMMERCIAL VALUE LEADERSHIP FOCUS adherium (ADR.ASX) • Establishment of • Payer / Provider-led reimbursement for digital strategies, as path to is a leader in the respiratory solutions payment and adoption adherence marke
Slide 6: The Adherium 1,2,3: Better outcomes, Path to Payment, Data analytics
The adherium 1,2,3 > 1) Better outcomes 2) Path to Payment 3) Data analytics 1 2 3 We provide connected solutions Supply the sensors and a data Provide reimbursement data to allow patients and physicians platform to our partners who can analytics and clinical data to better manage their disease bene
Slide 7: Adherium is well positioned to address the digital health adherence opportunity
adherium is well positioned to address the digital health adherence opportunity Why Adherence Technology? Why now? Changing market conditions triggering a tipping point in the opportunity: US$56b ~50% US$34b US economic of asthma and COPD Annual preventable burden of asthma patients fail to take US
Slide 8: Adherium's Hailie solution is the most clinically supported solution
adherium’s Hailie® solution is the most-clinically supported solution to improved medication adherence among asthma and COPD patients Patients Clinicians, Providers & Payers ® Hailie® Sensor Hailie® Mobile App Hailie® Clinician Web Portal Patients know exactly when they have to Clinicians and provid
Slide 9: In the last four years, we have made significant progress
In the last four years, we have made significant progress to enhance and distribute our technology, while preparing for growth Commercial Product • ~170,000 sensors sold globally • Sensor set with broad US market coverage for asthma and COPD medications (80%) • Further development of our current rel
Slide 10: New focus based on learnings and evolving market conditions
Based on learnings from our experience and evolving market conditions, we have now a new focus to address the opportunity Changing Market Conditions Our Learning from Experience • Direct to Consumer strategy failed due to lack of Healthcare Digital health Providers are physician endorsement needs to
Slide 11: Our New Focus: CPT codes and risk share
Our New Payer- and provider-led strategies where path to payment is clear. Focus (e.g. risk/reward, CPT codes) ▪ CPT code :- Remote Patient Monitoring ▪ Risk Share COPD > Partner with patient ‒ Three Remote Patient Monitoring codes management service ‒ Required a physiological measure captured ‒ Pro
Slide 12: Our New Focus: Data and reimbursement-compliant reporting
Our New Payer- and provider-led strategies where path to payment is clear. Focus (e.g. risk/reward, CPT codes) Patient reports and alerts Online interfaces ® • Reimbursement- Data compliant data Reimbursement-compliant reports • On-demand data management Billing support for clinicians and analytics
Slide 13: Our New Focus: Commercialisation in US and UK
Our New Commercialisation in US and UK Strategic pricing entries in UK, Focus Canada and Australia Market readiness in China, Japan MARKET READINESS PRICING STRATEGY COMMERCIALISATION US and Canada • Identify distribution partners Pricing strategy developed to ensure target • Partner with Respirator
Slide 14: Our New Focus: Clinician testimonials
Our New Commercialisation in US and UK Strategic pricing entries in UK, Focus Canada and Australia Market readiness in China, Japan “Devices like “90% of those who I see “As the bulk of asthma Smartinhalers will be the in the severe asthma is in primary care, the next big thing in asthma setting do
Slide 15: Our New Focus: Portfolio development
Portfolio development Our New driven by; 1) data generation to Focus support payment 2) expansion to COPD Rescue/Reliever Preventer Current GSK Diskus Advair GSK Ventolin HFA Teva ProAir HFA GSK Advair HFA GSK Flovent HFA AZ Symbicort / Flovent Proposed Future Development Merck Proventil BI Respimat
Slide 16: Work to date: new Hailie devices and AstraZeneca
Work to date has focussed on supply for clinical trials and limited commercial evaluations • Completed development for four new devices which incorporate Hailie® technology: AstraZeneca’s Symbicort® pMDI, Symbicort® Turbuhaler®, Bricanyl® Turbuhaler®, and Bevespi®. The Symbicort® Turbuhaler® and Bri
Slide 17: Building the Bridgehead over the next two years
Building the Bridgehead over the next two years 1 2 3 4 Partnership-enabled Step change in UK reimbursement New partnerships commercialization in the our relationship with & NHS commercialization to deliver our next- US, Canada and ROW AstraZeneca (AZ) as strategic pillar generation product to ROW g
Slide 18: From Bridgehead to Sustainable Business
From Bridgehead to Sustainable Business Drive patient numbers & data capture Aim to commercialise sensors with physiological measures to access new digital CPT codes in the US Building the Anticipate move to data bridgehead monetization leveraging the Focused Commercialisation Summatix platform Stre
Slide 19: Proven Leadership Team
Proven Leadership Team Significant commercialisation strategy experience with proven track record in globally Thomas Lynch Peter Stratford Mike Motion Rob Turnbull Chairman Chief Executive Officer Chief Commercial Officer General Manager • Moved multiple offshore • Proven track record of bringing •
Slide 20: Conclusion
Conclusion Key Drivers... ...Our Goal Ever growing burden of respiratory and broader chronic Evolving patients base - Through leadership in digital solutions diseases living longer, that improve adherence we will address needs 25m with chronic diseases, across the end-end healthcare system: and incr
Slide 21: Capital Raise Summary
Capital Raise Summary Transaction Structure Use of Funds • A pro rata Offer via a 1 for 1 non-renounceable Next generation Hailie® rights issue of ~180m New Shares to raise up to sensors incorporating $5.4m $2.7m physiological measures and • The offer price is A$0.03 per share extended portfolio for
Slide 22: Indicative Timeline
Indicative Timeline Activity Use of Indicative Funds Dates ASX Announcement of Rights Issue Offer Wednesday, 11 December 'ex' date Friday, 13 December Record date for Rights Issue Offer Monday, 16 December Dispatch of Offer Booklet and Rights Issue Offer opens Thursday, 19 December Rights Issue Offe
Slide 23: Risks
Risks Shareholders should consider the investment in the context of their individual risk (a) Business risks - Eligible Shareholders should consider the various risks and profile for speculative investments, investment objectives and individual financial difficulties frequently encountered by compan
Slide 24: Risks (continued)
Risks (continued) hospitals and Payers. Failure to retain existing customers or attract new manufacturing defects will not arise. Adherium may be exposed to the risk of customers would materially impact the Company’s ability to generate revenue product liability claims, which are inherent in the des
Slide 25: Slide 25